Allan J W Lui

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 8

Top Topics

Chemotherapy Induced

Tyrosine Kinase

Top Venues

Clinical cancer research : an official journal of the American Association for Cancer Research

JCO precision oncology

Cancer research

This page only lists publications with an associated author ORCID identifier.

Publications

Tom Zhang, Christopher Antonio Febres-Aldana, Zebing Liu, Jenna-Marie Dix, Ryan Cheng, Raymond G Dematteo, Allan J W Lui, Inna Khodos, Leo Gili, Marissa S Mattar, Jeanine Lisanti, Charlene Kwong, Irina Linkov, Murray J Tipping, Elisa De Stanchina, Igor Odintsov, Marc Ladanyi, Romel Somwar
HER2 antibody-drug conjugates are active against desmoplastic small round cell tumor. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Arielle Elkrief, Igor Odintsov, Roger S Smith, Morana Vojnic, Takuo Hayashi, Inna Khodos, Vladimir Markov, Zebing Liu, Allan J W Lui, Jamie L Bloom, Michael D Offin, Charles M Rudin, Elisa De Stanchina, Gregory J Riely, Romel Somwar, Marc Ladanyi
Combination of MDM2 and Targeted Kinase Inhibitors Results in Prolonged Tumor Control in Lung Adenocarcinomas With Oncogenic Tyrosine Kinase Drivers and MDM2 Amplification. JCO precision oncology 8 (2024)
Isao Miyazaki, Igor Odintsov, Keiji Ishida, Allan J W Lui, Masanori Kato, Tatsuya Suzuki, Tom Zhang, Kentaro Wakayama, Renate I Kurth, Ryan Cheng, Hidenori Fujita, Lukas Delasos, Morana Vojnic, Inna Khodos, Yukari Yamada, Kota Ishizawa, Marissa S Mattar, Kaoru Funabashi, Qing Chang, Shuichi Ohkubo, Wakako Yano, Ryuichiro Terada, Claudio Giuliano, Yue Christine Lu, Annalisa Bonifacio, Siddharth Kunte, Monika A Davare, Emily H Cheng, Elisa de Stanchina, Emanuela Lovati, Yoshikazu Iwasawa, Marc Ladanyi, Romel Somwar
Author Correction: Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations. Nature cancer (2023)
Isao Miyazaki, Igor Odintsov, Keiji Ishida, Allan J W Lui, Masanori Kato, Tatsuya Suzuki, Tom Zhang, Kentaro Wakayama, Renate I Kurth, Ryan Cheng, Hidenori Fujita, Lukas Delasos, Morana Vojnic, Inna Khodos, Yukari Yamada, Kota Ishizawa, Marissa S Mattar, Kaoru Funabashi, Qing Chang, Shuichi Ohkubo, Wakako Yano, Ryuichiro Terada, Claudio Giuliano, Yue Christine Lu, Annalisa Bonifacio, Siddharth Kunte, Monika A Davare, Emily H Cheng, Elisa de Stanchina, Emanuela Lovati, Yoshikazu Iwasawa, Marc Ladanyi, Romel Somwar
Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations. Nature cancer 4 (9) (2023)
Alison M Schram, Igor Odintsov, Madelyn Espinosa-Cotton, Inna Khodos, Whitney J Sisso, Marissa S Mattar, Allan J W Lui, Morana Vojnic, Sara H Shameem, Thrusha Chauhan, Jean Torrisi, Jim Ford, Marie N O'Connor, Cecile A W Geuijen, Ron C J Schackmann, Jeroen J Lammerts van Bueren, Ernesto Wasserman, Elisa De Stanchina, Eileen M O'Reilly, Marc Ladanyi, Alexander E Drilon, Romel Somwar
Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements. Cancer discovery 12 (5) (2022)
Igor Odintsov, Michael V Ortiz, Inna Khodos, Marissa S Mattar, Allan J W Lui, Shinji Kohsaka, Elisa De Stanchina, Julia L Glade Bender, Marc Ladanyi, Romel Somwar
CIC-Mediated Modulation of MAPK Signaling Opposes Receptor Tyrosine Kinase Inhibitor Response in Kinase-Addicted Sarcoma. Cancer research 82 (6) (2022)
Igor Odintsov, Allan J W Lui, Whitney J Sisso, Eric Gladstone, Zebing Liu, Lukas Delasos, Renate I Kurth, Exequiel M Sisso, Morana Vojnic, Inna Khodos, Marissa S Mattar, Elisa de Stanchina, Shawn M Leland, Marc Ladanyi, Romel Somwar
The Anti-HER3 mAb Seribantumab Effectively Inhibits Growth of Patient-Derived and Isogenic Cell Line and Xenograft Models with Oncogenic NRG1 Fusions. Clinical cancer research : an official journal of the American Association for Cancer Research 27 (11) (2021)
Hiroki Sato, Adam J Schoenfeld, Evan Siau, Yue Christine Lu, Huichun Tai, Ken Suzawa, Daisuke Kubota, Allan J W Lui, Besnik Qeriqi, Marissa Mattar, Michael D Offin, Masakiyo Sakaguchi, Shinichi Toyooka, Alexander E Drilon, Neal X Rosen, Mark G Kris, David Solit, Elisa De Stanchina, Monika A Davare, Gregory J Riely, Marc Ladanyi, Romel Somwar
MAPK Pathway Alterations Correlate with Poor Survival and Drive Resistance to Therapy in Patients with Lung Cancers Driven by ROS1 Fusions. Clinical cancer research : an official journal of the American Association for Cancer Research 26 (12) (2020)